Follow on Google News News By Tag * Pharmaceutical * Healthcare * Ratings * Medical * Imf * Drug * Reimbursement * Regime * Serbian * Insurance * More Tags... Industry News Country(s) Industry News
Follow on Google News | "Serbia Pharmaceuticals & Healthcare Report Q4 2010" now available at Fast Market ResearchNew Healthcare research report from Business Monitor International is now available from Fast Market Research
By: Fast Market Research In August 2010, local newspaper Blic reported that the authorities are expecting to roll out new electronic health cards for insurance purposes within the next two to three years, at a total cost of around EUR300,000. The cards are to be used both for medical services and for dispensation of prescriptions, which should facilitate better administration and monitoring of insurance contributions. The pilot programme, currently underway in the Valjevo area, will be assessed before the commencement of a national roll-out. However, health finances as a whole will remain restricted by high unemployment rates as well as International Monetary Fund (IMF) demands on government spending. Consequently, we expect the generics segment to be the key beneficiary, posting a compound annual growth rate (CAGR) of 7.70% in local currency terms through to 2014 and accounting for almost two-thirds of the total market by value. At the same time, the five-year CAGR of the whole market will be 6.83% (or just 2% in US dollar terms, with its value rising from RSD73.0bn (US$1.08bn) in 2009 to RSD101.6bn (US$1.20bn) in 2014. However, growth rates will be hampered by downward pressures on prices through reimbursement listings, as well as by patent expirations. That said, risks to Serbia's recovery remain. For one thing, the regional economy is still weak, with many of Serbia's peers and trading partners struggling to emerge from recession. Furthermore, the Serbian dinar has depreciated markedly since late-2008, and any further downside would put additional pressure on households that took out loans in foreign currencies such as the euro and the Swiss franc during boom years. Finally, although we welcome the IMF's decision in June 2010 to approve a US$472.9mn tranche of Stand-By Arrangement financing, we caution the Serbia's fiscal position remains outside IMF requirements, with the necessary budgetary retrenchment providing a potential drag on the country's 2010 growth prospects. For more information or to purchase this report, go to: - http://www.fastmr.com/ Partial Table of Contents: Executive Summary SWOT Analysis - Serbia Pharmaceuticals And Healthcare Industry SWOT - Serbia Political SWOT - Serbia Economic SWOT - Serbia Business Environment SWOT Pharmaceutical Business Environment Ratings - Table: Emerging Europe Regional Pharma Business Environment Ratings for Q410 - Rewards - Risks Serbia - Market Summary Regulatory Regime - Table: The Number of Products on the Drugs List - Intellectual Property Environment - Pricing Regime - Price Cuts - Price Rises - Reimbursement Regime - Table: Reimbursement by ATC Categories in 2008 and 2009 - Table: Serbia - Examples of Reimbursed Medicines by Category Industry Developments - Epidemiology - Communicable Diseases - Non-Communicable Diseases - Table: Disease Burden In CEE - Healthcare Sector - Table: Serbia - Major General And Specialised Hospitals - Recent Healthcare Sector Developments - Healthcare Insurance - Healthcare Reform - Medical Tourism - Table: Serbia - Cosmetic Surgery Costs - Clinical Trials - Table: Number Of Ongoing Clinical Trials In Serbia - Medical Devices - Table: Medical Device Classification In Serbia Industry Forecast Scenario - Overall Market Forecast - Key Growth Factors - Industry - Key Growth Factors - Macroeconomic - Table: Serbia - Economic Activity - Prescription Drug Market Forecast - Table: Serbia - Defined Daily Dose (DDD) Per 1,000 Inhabitants - Patented Drug Market Forecast - Generic Drug Market Forecast - OTC Medicine Market Forecast - Table: Serbia - Sales Of Herbal Remedies 2007 - Medical Device Market Forecast - Pharmaceutical Trade Forecast - Other Healthcare Data Forecasts - Key Risks to BMI's Forecast Scenario Competitive Landscape - Investment Climate - Pharmaceutical Industry - Table: Companies Involved In The Serbian Pharmaceutical Industry - Domestic Pharmaceutical Industry - Domestic Company Activity - Foreign Pharmaceutical Industry - Table: Proposed Members Of Serbia's Pharmaceutical Industry Association - Foreign Company Activity - Pharmaceutical Wholesale And Retail Company Monitor - Indigenous Company Profiles - Hemofarm (Stada) - Full Table of Contents is available at: -- http://www.fastmr.com/ About Business Monitor International Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. End
|
| |||||||||||||||||||||||||||||||||||||||||||
Account Phone Number